Billy Joel diagnosed with normal pressure hydrocephalus: What is it?
'Under his doctor's instructions, Billy is undergoing specific physical therapy and has been advised to refrain from performing during this recovery period,' the message reads, in part.
Normal pressure hydrocephalus is a condition caused by a buildup of cerebrospinal fluid in the ventricles of the brain, Johns Hopkins School of Medicine explains. Such a buildup could be the result of a number of factors, including a brain tumor, a brain infection or a head injury, but it's more often diagnosed among older adults, the agency said.
It's also 'relatively uncommon' in general, Cleveland Clinic says, with about 0.2% of people under 65 having the diagnosis, and about 5.9% over 80 suffering from the condition.
Symptoms of normal pressure hydrocephalus (NPH) are bucketed into three categories, according to the Hydrocephalus Association: those that affect walking, those that affect cognitive abilities, and those that affect bladder control. Patients may have trouble going down stairs, taking long strides or maintaining balance; experience forgetfulness, disinterest or confusion; and have trouble controlling their bladders.
In Friday's message, Billy Joel was said to be experiencing problems with his vision, hearing and balance — symptoms that have only been 'exacerbated' by recent performances.
Early signs of NPH are also often misdiagnosed as Alzheimer's or Parkinson's, according to researchers: Both the Alzheimer's Association and the Hydrocephalus Association estimate that around 80% of cases are wrongly diagnosed.
'Neuropsychological testing is the most accurate means of determining and documenting cognitive strengths and problems and can help provide a more accurate diagnosis of the range of neuropsychological and cognitive issues,' the Hydrocephalus Association says.
The good news is that NPH can be treated and managed, most commonly by implanting a shunt — or a small tube — into the brain ventricles to drain the excess cerebrospinal fluid into another part of the body (usually the abdomen) where it can be absorbed.
Those who respond well to the procedure can see 'rapid improvement' in their behavior (usually with walking at first), but it could take much longer for the full results, or for the symptoms to be reversed, the Hydrocephalus Association says.
Joel, 76, has not revealed details of his treatment plan, but his message indicated he's 'fully committed to prioritizing his health.'
His scheduled shows — now all canceled — had extended into July 2026.
'I'm sincerely sorry to disappoint our audience, and thank you for understanding,' he wrote in a statement included with the message.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Forbes
3 hours ago
- Forbes
How AI Is Transforming Healthcare In 2025
Ashish Sukhadeve, Founder and CEO of Analytics Insight, providing organizations with strategic insights on disruptive technologies. In terms of its transformative effect, AI is doing for healthcare what electricity did for the industry. According to Fortune Business Insights, the global AI healthcare market was valued at $29.01 billion in 2024, and it's projected to grow to $504.17 billion by 2032. This represents a massive CAGR of 44%. For healthcare leaders, the time to act is now; AI is rapidly advancing areas such as illness prevention, diagnostics and drug discovery, and it has the potential to significantly reduce administrative burdens. Here are just some of the areas to follow when it comes to AI in the sector: Preventing Illness I think one of AI's most valuable contributions is its ability to prevent illness. There are many wearables, AI health apps and the Internet of Medical Things (IoMT) available now. These consumer applications enable individuals to take charge of their own health. They allow users to monitor everything from heart rates to sleep cycles, turning passive patients into proactive participants. Doctors also benefit. AI helps them understand a patient's daily habits, risks and medical history. This improves their ability to offer personalized care. I see prevention, powered by data, as becoming the new normal. Diagnosis AI also excels in medical imaging and diagnostics. At Massachusetts General Hospital and MIT, AI detected lung nodules with 94% accuracy, outperforming radiologists, who achieved 65%. Similar results have been found for breast cancer detection. According to the Harvard School of Public Health, AI in diagnostics may reduce treatment costs by 50% and improve outcomes by 40%. AI is not just reducing medical errors; it is reducing medical anxiety. I believe with AI improving both accuracy and outcomes, healthcare leaders must treat diagnostics not as a back-office upgrade, but as a frontline opportunity for transformation. Drug Discovery Bringing a drug to market can take over 10 years and cost $172 million on average. Only 13.8% of compounds make it to approval. AI can help reduce this timeline dramatically. Systems like IBM Watson can process vast amounts of medical journals and case studies. DeepMind uses neural networks to solve complex health problems with learning algorithms. AstraZeneca's AI, trained on data from 500,000 people, can now predict diseases like Alzheimer's before symptoms appear. These tools can be used not only to improve timelines but also to save countless lives. Caring For The Aging Population As populations age, the demand for elder care rises. AI-powered robots are easing this burden, even when it comes to things like laundry. They are increasingly used to assist in physical therapy, provide companionship and reduce hospital visits. These machines can now hold conversations that stimulate mental engagement in older adults. The lesson is clear: Embracing AI not only addresses labor shortages but also opens new paths to compassionate, scalable elder care. Administration Support AI is improving what patients don't see, the administration. Microsoft's Dragon Copilot can create real-time notes during clinical consultations. Germany's Elea AI reports that it can cut testing and diagnosis from "weeks to hours." These and many other tools are giving doctors more time focusing on patient care. These tools are also helping save time when it comes to clinical decision making, and as evidenced by the Alzheimer's prediction example, AI increasingly supports early warnings. It can now identify high-risk patients using data patterns, including genetic and lifestyle factors. Tools like ChatRWD are replacing and outperforming generic AI models. Conclusion AI is not replacing doctors but empowering them. It now impacts every layer of healthcare, from diagnosis to prevention, from robots to research. Patients can be better informed. Doctors are better equipped. Systems are more efficient. In 2025, I believe the most important medical tool is not a scalpel; it's data, and AI is the surgeon. The future of healthcare is not waiting on some distant horizon; it's already here.
Yahoo
3 hours ago
- Yahoo
New Alzheimer's Clinical Guidelines Move Towards Replacing More Invasive Tools with Blood Tests; Pressing Need for Further Guidance Remains
Alzheimer's Drug Discovery Foundation calls for guidelines for FDA-approved blood tests to continue momentum toward precision medicine NEW YORK, July 30, 2025 /PRNewswire/ -- Expanding the use of Alzheimer's blood tests is crucial to usher in a new era of precision medicine and bring Alzheimer's disease into mainstream care. The new clinical practice guidelines for blood biomarkers announced today by the Alzheimer's Association represent a first step in this effort, but further direction is needed to address newly FDA-approved tests as the diagnostic landscape continues to evolve. "Replacing more invasive PET scans and CSF tests, when appropriate, with blood tests will be a major step toward the future we envision, where we can detect and diagnose Alzheimer's sooner, allowing for earlier intervention and even prevention," said Dr. Howard Fillit, Co-Founder and Chief Science Officer of the ADDF. "These guidelines signal progress, but with the science moving quickly, it's essential that clinical recommendations keep pace – especially with Fujirebio's blood test approved by the FDA and more to follow." The new guidelines are limited to specialty care, apply only to patients with cognitive impairment, and exclude several blood tests, including Fujirebio's. Still, they reflect critical momentum, recommending blood biomarkers with ≥90% sensitivity and specificity to replace more invasive and costly confirmatory tests like PET imaging or cerebrospinal fluid (CSF) testing during Alzheimer's diagnosis. As of now, only C2N's PrecivityAD2 test meets these requirements. Tests with ≥90% sensitivity and ≥75% specificity are recommended to be used for triage, with negative results ruling out Alzheimer's, while positive results should be confirmed with PET or CSF. While amyloid blood tests are a critical first step, the ADDF is focused on advancing next-generation biomarkers through its Diagnostics Accelerator (DxA) – a $100 million global initiative supported by the late Leonard A. Lauder, Bill Gates, Jeff Bezos, and other leading philanthropists – that reflect the broader biology of aging and align with today's robust drug pipeline where over 70% of drugs target non-amyloid pathways. "The future of Alzheimer's care lies in precision medicine. To get there, we need a full spectrum of validated biomarkers — and robust clinical guidelines to help providers use them effectively," added Dr. Fillit. "In the future, digital biomarkers and blood tests will be used side-by-side to detect the disease early, track its progression, and guide treatment based on each patient's unique biology." About The Alzheimer's Drug Discovery Foundation (ADDF)Founded in 1998 by Leonard A. and Ronald S. Lauder, the Alzheimer's Drug Discovery Foundation is dedicated to rapidly accelerating the discovery of drugs to prevent, treat and cure Alzheimer's disease. The ADDF is the only public charity solely focused on funding the development of drugs for Alzheimer's, employing a venture philanthropy model to support research in academia and the biotech industry. The ADDF's leadership and contributions to the field have played a pivotal role in bringing the first Alzheimer's PET scan (Amyvid®) and blood test (PrecivityAD®) to market, as well as fueling the current robust and diverse drug pipeline. Through the generosity of its donors, the ADDF has awarded more than $370 million to fund 765 Alzheimer's drug discovery programs, biomarker programs and clinical trials in 21 countries. To learn more, please visit: About the Diagnostics Accelerator (DxA)The Diagnostics Accelerator, created in July 2018, is a $100 million global research initiative from partners including ADDF Co-Founder Leonard A. Lauder, Bill Gates, Jeff Bezos, MacKenzie Scott, the Dolby family, the Charles and Helen Schwab Foundation, The Association for Frontotemporal Degeneration, among others, to develop novel biomarkers for the early detection of Alzheimer's disease and related dementias. This research initiative is dedicated to accelerating the development of affordable and accessible biomarkers to diagnose Alzheimer's disease and related dementias and advance the clinical development of more targeted treatments. Through translational research awards and access to consulting support from industry experts, this program will challenge, assist and fund the research community in both academia and industry to develop novel peripheral and digital biomarkers. View original content to download multimedia: SOURCE Alzheimer's Drug Discovery Foundation Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
CNN
5 hours ago
- CNN
Food assistance benefits are tied to slower cognitive decline in older adults, new study suggests
For older adults who may otherwise be food-insecure, participating in food assistance benefits may be associated with a slower cognitive decline as they age, according to new research. Compared with eligible people who were not participating in the US Supplemental Nutritional Assistance Program, SNAP participants showed a slower decline in cognitive function during a 10-year period, essentially maintaining up to three additional years of cognitive health, according to the study presented Wednesday at the Alzheimer's Association International Conference in Toronto. 'We expected that SNAP might be protective for cognitive health based on prior research linking food insecurity to faster cognitive decline. But what did surprise us was the persistence of the effect over a decade — and the fact that the benefit was equivalent to preserving two to three extra years of cognitive health,' Linlin Da, lead author of the study and a Ph.D. candidate in health services research at the University of Georgia, said in an email. 'This study is important because it shows that supporting basic needs like food access can have long-term benefits for brain health, something not widely recognized,' Da said. 'In a time when we're seeking ways to delay or prevent Alzheimer's disease and related dementia, this suggests that public health and social policy can play a role alongside medical approaches.' It's estimated that nearly 37% of SNAP participants are in households with older adults or people with disabilities, and on average, SNAP participants may receive an estimated $6.16 per day per person in benefits. SNAP, known previously as the Food Stamp Program, helped an average of more than 41 million low-income people in the United States in a typical month last year, according to the Center on Budget and Policy Priorities. Now, President Trump's One Big Beautiful Bill Act makes the largest cuts to food stamps in the program's 86-year history, jeopardizing assistance for millions of people. The nonpartisan Congressional Budget Office estimates that the law will reduce federal spending on SNAP by almost $187 billion over the next decade. Some public health experts worry that while cuts to SNAP would lead to budgetary savings, it also could produce higher rates of food insecurity and poorer health outcomes in the long run, according to the nonprofit KFF, formerly known as the Kaiser Family Foundation. And some Democratic state leaders are warning about potential consequences. 'During a time when many American families are already struggling, food assistance programs such as SNAP are more essential than ever,' Illinois Gov. JB Pritzker said in a news release Tuesday. 'Under the veneer of 'cost savings,' the Trump Administration is slashing benefits and threatening the well-being of hundreds of thousands of Illinoisans, putting their health and welfare at risk. Our state deserves better.' The researchers on the new study, from the University of Georgia, analyzed data on more than 2,000 adults 50 and older across the United States. About half of them were enrolled in SNAP in 2010, and the other half were eligible for SNAP but did not participate in the program. Every two years between 2010 and 2020, the researchers interviewed the study participants to assess their cognition, memory and executive function, including their ability to carry out tasks or to plan. Each person was given a cognitive score based on the assessments. The assessments, which have not yet been published in a peer-reviewed journal, showed that those enrolled in SNAP had a slower rate of cognitive decline in cognition, memory and executive function during the 10-year period. 'The decline in global cognitive function was 0.10 points slower per year for SNAP participants compared to nonparticipants,' Da said. 'While that may sound small, over a 10-year period, this adds up to about one full point of preserved cognition. To put it in clinical terms, this slower decline could delay the onset of mild cognitive impairment by nearly a decade for someone starting at a healthy cognitive baseline.' When the researchers analyzed their data by race and ethnicity, they found that there was a slightly faster decline in cognition and memory among Black and Hispanic adults compared with White adults, but no significant racial differences were observed for executive function. However, SNAP participation was linked with much stronger cognitive benefits and slower decline among the White adults. As a 10-year study, the new research covers 'a good length of time' to determine the benefits of diet and SNAP as associated with cognitive health, Dr. Shae Datta, a neurologist at NYU Langone Health and brand partner for the supplement company Qunol, said in an email. 'Having the means to buy nutritious food is important for preventing cognitive decline,' said Datta, who was not involved in the new study. 'This study suggested that SNAP participation, or any nutritional support program can delay the onset of cognitive impairment or dementia. Translating in a greater ability to manage their activities of daily living and remain independent longer.' While the new study suggests only an association between SNAP participation and cognitive decline, rather than a causal relationship, the researchers emphasized that not having adequate access to food can negatively affect cognitive function. SNAP participation may help improve someone's nutritional intake, thus potentially slowing cognitive decline. 'When people don't have access to healthy nutrition programs, they may have inadequate intake of, for example, brain healthy fats, omega-3 fatty acids, which are found in fish, fish like lake trout, mackerel, herring, albacore tuna, sardines and wild salmon,' said preventive neurologist Dr. Richard Isaacson, director of research at the Institute for Neurodegenerative Diseases in Florida, who was not involved in the new study. 'Having a balanced diet can neutralize a lot of the risk elements related to developing cognitive decline. The way that I would think about this is, the Mediterranean-style diet is by far the most evidence-based when it comes to reducing the risk of cognitive decline,' Isaacson said. 'But a Mediterranean-style diet is rich in green, leafy vegetables. Vegetables are expensive. Fatty fish are expensive. So nutrition assistance programs can really fill the gap.' A Mediterranean-style diet includes mostly vegetables, fruits, beans, nuts, lentils, whole grains and healthy fats, such as extra virgin olive oil and avocados. The diet may include a moderate amount of natural cheese and yogurt, but it is low in red meat and sugar. Overall, the potential health benefits of participating in a food assistance program for an older adult who otherwise would be food-insecure are based on whether that adult uses the program to access brain healthy foods while taking other steps to maintain cognitive health, said Isaacson, who established one of the first Alzheimer's prevention clinics in the United States. 'You can't eat a magic blueberry and think you're going to prevent Alzheimer's disease,' he said. 'Healthy nutrition, exercising on a regular basis, seeing a doctor regularly to control blood pressure, cholesterol, diabetes, vascular risk factors – you need to do all of these different things to have the most benefit.' CNN's Nathaniel Meyersohn contributed to this report.
